|
ÆÄ·º¼¿ ÄÚ¸®¾Æ |
ÆÄ·º¼¿ ÄÚ¸®¾Æ- CRA ¸ðÁý
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
03.04 |
|
|
ÆÄ·º¼¿ ÄÚ¸®¾Æ |
ÆĶô¼¿ ÄÚ¸®¾Æ -CRA
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
10.10 |
|
|
ÆÄ·º¼¿ ÄÚ¸®¾Æ |
ÆĶô¼¿ ÄÚ¸®¾Æ -CRA
¼¿ï °³²±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
09.04 |
|
|
ICON Clinical Research Korea |
Study Start-up Associate
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
04.22 |
|
|
º£½ºÆ®³×Æ®¿öÅ©(ÁÖ) |
Pharmacovigilance(drug safety) Specialist / ¿Ü±¹°è Á¦¾à
¼¿ï °³²±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
¸¶ÄÉÆÃ/±âȹ/±³À° |
2³â¡è |
ä¿ë½Ã |
05.14 |
|
|
½á¸ðÇǼŻçÀ̾ðƼÇÈ ÄÚ¸®¾Æ |
Technical Sales Specialist for Imaging, Biosciences
¼¿ï °³²±¸ | ´ëÇпø(¼®»ç) Á¹¾÷ |
»ó¹Ý±â »ç¿ø¸ðÁý |
2³â¡è |
ä¿ë½Ã |
02.16 |
|
|
(ÁÖ)»çÀ̳ؽº |
ÀǾàÇ°/ÀÇ·á±â±â ÀÓ»ó °³¹ß º»ºÎ PM
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
»ó½Ãä¿ë |
03.22 |
|
|
ICON Clinical Research Korea |
Jr. Clinical Research Associate(Oncology)
¼¿ï °³²±¸ | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
04.22 |
|
|
¾ÆÀÌÅ¥¾î(ÁÖ) |
Á¦¾à¿¬±¸¼Ò Ç°Áúº¸Áõ(DQA)ÆÀ ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Ç°Áú°ü¸®/Ç°Áúº¸Áõ |
2³â¡è |
ä¿ë½Ã |
08.21 |
|
|
(ÁÖ)´ºÆ®¸®¹ÙÀÌ¿ÀÅØ |
(ÁÖ)´ºÆ®¸®¹ÙÀÌ¿ÀÅØ È¨¼îÇοµ¾÷/¿Â¶óÀοµ¾÷ ÆÀÀå ¸ðÁý
¼¿ï °³²±¸ | Çз¹«°ü |
¸¶ÄÉÆÃ/±âȹ/±³À° |
2³â¡è |
ä¿ë½Ã |
08.20 |
|
|
½á³ÊÀκñÀÚ |
CRA ÇÁ¸®·£¼ ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
06.20 |
|
|
(ÁÖ)¿ø³×½º¿¡ÀÌÄ¡¾Ë |
¿Ü±¹°è- ÀÇ·á±â±â ¼¼ÀÏÁî
¼¿ï °³²±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
2³â¡è |
ä¿ë½Ã |
05.07 |
|
|
Å©·¹³Ê ÇコÄɾî |
Å©·¹³Ê MIS(Medical Information Service) ¾à»ç ±¸ÀÎ
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Çмú/±³À°/»ó´ã |
2³â¡è |
ä¿ë½Ã |
06.12 |
|
|
DOCS ICON Resourcing Solutions |
¿Ü±¹°è CRO-Study Authorization Associate (1¸í)
¼¿ï °³²±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
2³â¡è |
ä¿ë½Ã |
09.23 |
|
|
ºê·¹ÀÎÇãºê |
[ÇìµåÇåÆÃ]±Û·Î¹ú ¸ÞµðÄà Áø´ÜÀåºñ ȸ»ç-ÀÓ»ó °æ·ÂÀÚ Ã¤¿ë
¼¿ï °³²±¸ | ´ëÇÐ(2~3³â) ÀçÇÐ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
09.23 |
|